Pharmacokinetics (pk) and tolerance of infusional vincristine (vcr) for aggressive lymphomas indicate dose reductions for excretory organ dysfunction are not necessary
Year: 2008
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: D. E. Cole, F. M. Balis, N. Grant, T. White, K. Dunleavy, J. E. Janik, L. Whalen, W. Goodspeed, W. H. Wilson
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2590338714